Published in Women's Health Weekly, July 6th, 2006
The study is being conducted in Europe, in ovarian cancer patients that have relapsed after first line platinum therapy. The first patient was dosed with the study medication in France. The open-label trial is being managed by Cvitkovic and Associates (CAC), a clinical research organization (CRO) with a specialty in platinum drugs, and will accrue approximately 40 patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly